EOM 1352: Fri 7 June 2024, 11:36

Current Edition

Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
Europe

Myovant reports a Phase 3 success, but Wall Street isn’t cheered

An experimental drug from Myovant Sciences met its main goal in a Phase 3 trial of women with uterine fibroids, results which keep the biotech on track to file the d...
Continue Reading →
Europe

Pfizer, Merck KGaA’s latest Bavencio nod sets up 3-way kidney cancer battle

The FDA approved Pfizer and Merck KGaA's Bavencio in combination with Inlyta for the first-line treatment of patients with advanced kidney cancer. (Pfizer) Pfize...
Continue Reading →
Europe

Watch out, Dupixent. Pfizer’s new JAK inhibitor could come after your eczema market

In a possible relief for Pfizer and for abrocitinib as a JAK inhibitor, fewer patients on it than on placebo stopped therapy due to side effects. (Tracy Staton) P...
Continue Reading →
Asia Pacific

Trastuzumab deruxtecan demonstrated clinically-meaningful response in patients with refractory HER2-positive metastatic breast cancer

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced positive top-line results for the pivotal Phase II DESTINY-Breast01 trial of trastuz...
Continue Reading →
news

Cytokinetics, Astellas fall short in ALS trial, but spin a success story

Cytokinetics said Sunday its experimental drug failed a Phase 2 study of patients with amyotrophic lateral sclerosis, the neurodegenerative disease known as ALS. But...
Continue Reading →
news

Epidiolex sales beat Wall Street’s bar as GW Pharma reports trial success

GW Pharma's seizure medicine Epidiolex handily surpassed Wall Street forecasts for sales during the first quarter, and the biotech gave reason for further optimism b...
Continue Reading →
Europe

‘Pathbreaking’ Ionis trial offers way forward in Huntington’s disease

An experimental drug developed by Ionis Pharmaceuticals and Roche could offer a way forward to treat Huntington's disease, nearly three decades after researchers ...
Continue Reading →
Europe

GSK chases Trelegy asthma nod with mixed phase 3 results

An approval for GSK's Trelegy in asthma patients could help the company offset the continued fall of its long-time blockbuster Advair. (GlaxoSmithKline) With gen...
Continue Reading →
news

Awaiting FDA nod, Novartis touts latest data on gene therapy Zolgensma

Novartis' AveXis presented its latest interim Zolgensma data at the AAN annual meeting in Philadelphia on Sunday. (Pixabay) As Novartis waits for FDA action on i...
Continue Reading →
Europe

Roche’s breast cancer hopes get a boost from postsurgery Kadcyla approval

Kadcyla received an FDA nod for adjutant treatment of HER-2 positive breast cancer, hopefully offsetting declining sales of Roche's Herceptin. (Roche) As its onc...
Continue Reading →
Catalyst: 12th January 2026
Quotient